reports
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b...
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025 March 19, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient completed their fin...
Nicoxannonce que la visite finale du dernier patient a été effectuée d...
Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Communiqué de presseNicox annonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Résultats de l'étude attendus en mai 2025 Visite finale du dernier patient dans la partie américaine de l’étude de phase 3 Denali sur NCX 470 également réalisée, avec des résultats toujours prévus au troisième trimestre 2025 19 mars 2025 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Gr...
Nicox Extends Cash Runway into Q4 2025
Nicox Extends Cash Runway into Q4 2025 Press Release Nicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 monthsImmediate upfront payment from Vester Finance of €0.5 million extends the cash runway into Q4 2025, enabling focus on future growthOngoing discussions and business development outreach underway for NCX 470 U.S. partnershipTwo NCX 470 clinical readouts in 2025 – Whistler Mechanism of Action in Q2 2025 and Denali confirmatory Phase 3 in Q3 2025 March 6, 2025 – release at 7:30 am CETSop...
Nicox prolonge l’horizon de sa trésorerie jusqu’au quatrième trimestre...
Nicox prolonge l’horizon de sa trésorerie jusqu’au quatrième trimestre 2025 Communiqué de presseNicox prolonge l’horizon de sa trésorerie jusqu’au quatrième trimestre 2025 Financement flexible avec Vester Finance dans le cadre d’une ligne de financement en fonds propres portant sur un nombre maximal de 10.000.000 d’actions sur une durée de 24 moisPaiement initial immédiat de 0,5 M€ de Vester Finance prolongeant l’horizon de trésorerie au quatrième trimestre 2025 et permettant à la Société de se concentrer sur sa croissance futureDiscussions et démarches actives de recherche de partenaires...
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Prov...
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprostNew analysis provides additional data demonstrating differentiation of NCX 470Development activities on track for U.S. New Drug Application submission targeted in H1 2026 March 3, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR00130...
Nicox Announces Scientific Presentation and Conference Attendance in H...
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the NCX 470 Mont Blanc Phase...
Nicox confirme son éligibilité au PEA-PME
Nicox confirme son éligibilité au PEA-PME Communiqué de presseNicox confirme son éligibilité au PEA-PME22 janvier 2025 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, confirme son éligibilité au PEA-PME pour les 12 mois à venir. Pour les besoins de cette confirmation, les critères d'éligibilité des titres de la société Nicox au PEA-PME, prévus par l'article L 221-32-2 du code monétaire et financier, ont été appréciés conformément aux modalités prévues par l'article D 22...
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highl...
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3 2025 Fourth quarter 2024 Nicox Group revenue of €13.7 million Cash of €10.7 million as of December 31, 2024, following a €5.2 million debt repayment, which the Company estimates will finance it into the third quarter of 2025 January 21, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Eur...
Nicox : Point d’activité et résumé financier du quatrième trimestre 20...
Nicox : Point d’activité et résumé financier du quatrième trimestre 2024 Communiqué de presseNicox : Point d’activité et résumé financier du quatrième trimestre 2024 Recrutement du dernier patient dans l'étude clinique de phase 3 NCX 470 Denali (bimatoprost grenod) avec les premiers résultats attendus au troisième trimestre 2025 Revenu du Groupe Nicox de 13,7 millions d’euros pour le quatrième trimestre 2024Trésorerie de 10,7 millions d'euros au 31 décembre 2024, suite à un remboursement de 5,2 millions d'euros de dette. La Société estime être financée en conséquence jusqu’au troisième t...
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlie...
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Press ReleaseNicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont BlancNCX 470 partnering efforts will focus on routes for bringing the product to market in the U.S.Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 December 2, 2024 – release at 7:30 am CETSophia Antipolis, FranceN...
Nicox Announces Publication of the Adaptive Design Period of the NCX 4...
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification of the optimal dose of NCX 470 in the Mont Blanc trial, the first Phase 3 trial of NCX 470Both doses of NCX 470 ophthalmic solution tested, 0.065% and 0.1%, lowered intraocular pressure more than the comparator, latanoprost 0.005% ophthalmic solutionThe 0.1% NCX 470 concentration was chosen for the...
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial...
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024The Company estimates that it is financed into Q3 2025 October 17, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR00...
Nicox : Point financier sur le troisième trimestre 2024 et résultats f...
Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024 Communiqué de presseNicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024 Premiers résultats de l'étude clinique de phase 3 NCX 470 (bimatoprost grenod) attendus au troisième trimestre 2025Trésorerie de 19,7 millions d'euros au 30 septembre 2024, incluant le produit net estimé de la vente des redevances VYZULTA et le financement en fonds propres annoncés le 14 octobre 2024. La Société estime être financée jusqu’au troisième trimestre...
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox’s net share of the VYZULTA royalty to SoleusSoleus investing $1.5 million (€1.37 million) in Nicox shares, issued at €0.3144 per share, representing a 20% premium to the closing price on October 11, 2024, with attached warrants valued at $0.75 million (€0.69 million) at an exercise price of €0.5240 per share, representing a 100% premium to the closing price on October 11, 2024R...
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensin...
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royaltiesGlaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseasesNicox focused on continued Phase 3 development of lead drug-candidate, NCX 470 September 23rd, 2024 – release at ...
Nicox Announces Approval of ZERVIATE in China
Nicox Announces Approval of ZERVIATE in China Press Release Nicox Announces Approval of ZERVIATE in China Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China will add a further royalty revenue stream for Nicox September 18, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Chinese partner, Ocumension Therapeutics, has received approval of the New Drug Application (NDA) to comme...
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi ...
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and TrophosMichele Garufi, former Chairman and CEO of Nicox, hands over his Board position after over more than 25 years at the company he co-foundedThe Nicox Board has now been entirely renewed to bring in the expertise to support the Company’s strategic direction going forward September 4th, 2024 – release at 7:30 am CET So...
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 ...
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Press Release Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Recruitment continues in China, on track for topline results in H2 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont Blanc July 25, 2024 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the recruitment and randomization of the last patient in the...
Nicox announces attendance at upcoming conferences
Nicox announces attendance at upcoming conferences Press Release Nicox announces attendance at upcoming conferencesJuly 19th, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its attendance at several upcoming international conferences: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 (Virtual) H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024 (New York) Investor Access, October 15-16, 2024 (Paris) AAO (American...
Nicox Provides Second Quarter 2024 Update
Nicox Provides Second Quarter 2024 Update Press Release Nicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue1 €1.0 million) for second quarter 2024Nicox Group cash of €7.8 million on 30 June 2024 which finances the Company until at least February 2025 July 18th, 2024 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position for Nicox SA and its subsidiaries (the “Nicox Group”) for the second quarter of 2024 and provided an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.